| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
OBJECTIVE: To provide the obstetrician-gynecologist with the recent advances in mechanisms of chemotherapy resistance in ovarian cancer. DATA SOURCES: A computerized search of articles published through September 1997 was performed on the MEDLINE Ovid and Cancerlit databases. Additional references were identified from the reference section of all selected papers. METHODS OF STUDY SELECTION: All identified references were evaluated as to their relevant contribution to our understanding of the basic mechanisms underlying the response to chemotherapy, the development of chemotherapy resistance in ovarian cancer, and possible strategies for therapy. TABULATION, INTEGRATION, AND RESULTS: One hundred sixteen references were reviewed. A brief summary of the classic concepts on resistance to cisplatin and paclitaxel is provided, followed by a description of the basic mechanisms governing apoptosis and cell cycle arrest as well as their involvement in cell response to chemotherapy and the development of chemoresistance. Finally, a brief summary of the molecular alterations described in ovarian cancer, together with hypothetic strategies for gene-targeted therapy, are reported. CONCLUSION: Cisplatin or paclitaxel chemotherapy induces arrest of the cell cycle or apoptosis in ovarian cancer cells. Tumor suppressor genes such as p53 play a paramount role in mediating this response and p21wAF1/CIP1 is a major mediator of p53-induced arrest of the cell cycle. Molecular alterations involving these tumor suppressor genes are related to the development of resistance to chemotherapy and represent possible targets for gene therapy in ovarian cancer.
This article has been cited by other articles:
|
|
 |
|
  H. K. Koblish, S. Zhao, C. F. Franks, R. R. Donatelli, R. M. Tominovich, L. V. LaFrance, K. A. Leonard, J. M. Gushue, D. J. Parks, R. R. Calvo, et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo Mol. Cancer Ther., January 1, 2006; 5(1): 160 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Jazaeri, C. S. Awtrey, G. V.R. Chandramouli, Y. E. Chuang, J. Khan, C. Sotiriou, O. Aprelikova, C. J. Yee, K. K. Zorn, M. J. Birrer, et al. Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers Clin. Cancer Res., September 1, 2005; 11(17): 6300 - 6310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Opipari Jr., L. Tan, A. E. Boitano, D. R. Sorenson, A. Aurora, and J. R. Liu Resveratrol-induced Autophagocytosis in Ovarian Cancer Cells Cancer Res., January 15, 2004; 64(2): 696 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, N. Yang, J.-R. Conejo Garcia, A. Mohamed, F. Benencia, S. C. Rubin, D. Allman, and G. Coukos Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma Am. J. Pathol., December 1, 2002; 161(6): 2295 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Levesque, D. Katsaros, M. Massobrio, F. Genta, H. Yu, G. Richiardi, S. Fracchioli, A. Durando, R. Arisio, and E. P. Diamandis Evidence for a Dose-Response Effect between p53 (but not p21WAF1/Cip1) Protein Concentrations, Survival, and Responsiveness in Patients with Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy Clin. Cancer Res., August 1, 2000; 6(8): 3260 - 3270. [Abstract] [Full Text]
|
|
|
|
|
|
K. Lessan, D. J. Aguiar, T. Oegema, L. Siebenson, and A. P. N. Skubitz CD44 and ß1 Integrin Mediate Ovarian Carcinoma Cell Adhesion to Peritoneal Mesothelial Cells Am. J. Pathol., May 1, 1999; 154(5): 1525 - 1537. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
